Wockhardt shareholders reject proposal to raise Rs 1,600 cr from promotor

The board of Mumbai-based drug firm had sought shareholder approval for a related party transaction with Khorakiwala Holdings and Investments to raise up to Rs 1,600 crore for a period of 5 years

Wockhardt chairman Habil Khorakiwala
Press Trust of India New Delhi
2 min read Last Updated : Aug 21 2023 | 4:22 PM IST

Shareholders of Wockhardt have rejected a proposal to raise Rs 1,600 crore from a promoter entity, according to a regulatory filing.

The board of Mumbai-based drug firm had sought shareholder approval for a related party transaction with Khorakiwala Holdings and Investments Pvt Ltd (KHIPL) to raise up to Rs 1,600 crore for a period of five years.

KHIPL, a promoter entity, is an RBI registered NBFC.

About 50.12 per cent votes came in against the proposal while 49.87 per cent of the votes polled favoured the resolution, Wockhardt said in a regulatory filing.

In a note, proxy advisory firm IiAS said it had sought approval for the proposal but it was defeated.

"Wockhardt's resolution for a related party transaction with Khorakiwala Holdings and Investments Pvt Ltd (KHIPL) for an amount up to Rs 1,600 crore for a period of five years, was defeated," it noted.

IiAS said the proposed related party transaction with KHIPL was intended for borrowing of funds for an amount up to Rs 1,600 crore for a period of two years renewable by mutual consent, subject to ratification by members at least once in every five years, IiAS said.

Supporting the proposal, the proxy advisory firm had stated that in order to meet its various operational and cash flow requirements on short notice, Wockhardt requires additional funds which KHIPL can provide through given its nature of business.

Shareholders, however, approved a proposal to raise up to Rs 1,600 crore through a qualified institutions placement (QIP) to eligible investors through an issuance of shares or other eligible securities.

Wockhardt is looking to turnaround its business operations with restructuring of the US business, vaccine tie-up with Serum for vaccine manufacturing in the UK among others.

The drug firm reported last week that its consolidated loss after tax widened to Rs 136 crore in the June quarter due to higher expenses.

The company had posted a consolidated loss after tax of Rs 75 crore in the April-June quarter a year-ago.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Corporate fundraisingWockhardtPharma sector

First Published: Aug 21 2023 | 4:22 PM IST

Next Story